Know Labs, Inc.: Business Overview, Financials & Competitive Analysis
Know Labs, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). High-risk medtech venture with differentiated technology undermined by pre-commercial status, financial distress, and strategic confusion following major ownership change. Know Labs possesses innovative patented technology with clear clinical applications in a large diabetes management market. However, the company faces significant headwinds: pre-revenue status for its core product, substantial accumulated.
What is Know Labs, Inc.'s industry? Know Labs, Inc. (knowlabs.com) operates in Medical Devices / Biotech - Diabetes Management & Non-invasive Diagnostics. AskCyborg classifies Know Labs, Inc. under Medical Devices / Biotech - Diabetes Management & Non-invasive Diagnostics in its company registry.
Know Labs is a US-based medical device company developing proprietary radio frequency dielectric spectroscopy (RFDS) technology for non-invasive health monitoring, primarily focused on continuous glucose monitoring fo...
Cyborg Score thesis
High-risk medtech venture with differentiated technology undermined by pre-commercial status, financial distress, and strategic...
Read the full analyst-debate transcript →Get the Latest Know Labs, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeKnow Labs, Inc. Overview
Pro stress-test →Know Labs is a US-based medical device company developing proprietary radio frequency dielectric spectroscopy (RFDS) technology for non-invasive health monitoring, primarily focused on continuous glucose monitoring for diabetes management. The company represents a classic pre-commercial biotech venture targeting FDA approval and commercialization of its innovative sensor platform.
Strategic Profile
Pro stress-test →Know Labs operates at the intersection of medical diagnostics and wearable technology, with a differentiated technology approach using electromagnetic spectroscopy to capture unique molecular signatures without invasive procedures. The company has recently undergone significant strategic transformation, with founder Ron Erickson continuing diagnostic research while new leadership pursues broader digital asset and blockchain initiatives following an acquisition by Greg Kidd's Goldeneye 1995, LLC in mid-2025.
Competitive Landscape
Pro stress-test →Know Labs competes in the continuous glucose monitoring (CGM) market against established players like Dexcom, Abbott FreeStyle Libre, and Medtronic Guardian. The non-invasive technology positioning offers potential differentiation if successfully commercialized, though numerous competitors pursue similar non-invasive glucose monitoring approaches. The company's recent pivot toward blockchain and digital assets creates uncertainty regarding competitive focus and resource allocation to core diagnostics business.
Industry Context
Know Labs, Inc. operates in Medical Devices / Biotech - Diabetes Management & Non-invasive Diagnostics.
Key facts
Founded: 1998 · Headquarters: Reno, Nevada